Preclinical and clinical data have shown that blocking the TF:FVIIa pathway can effectively inhibit tumor growth, as evidenced by the significant cytotoxic effects and promising clinical trial results observed with tisotumab vedotin, a TF-targeting antibody-drug conjugate [11,12]. The gene discussed is TF; the disease is neoplasm.